Literature DB >> 29872964

The interplay between bone and vessels in pediatric CKD: lessons from a single-center study.

Evgenia Preka1, Bruno Ranchin1, Anke Doyon2, Melody Vierge1, Tiphanie Ginhoux3, Behrouz Kassai3,4,5,6, Justine Bacchetta7,8,9.   

Abstract

OBJECTIVE: Mineral and bone disorders associated to chronic kidney disease (CKD-MBD) are a daily challenge for pediatric nephrologists, with a significant risk of long-term bone and vascular comorbidities.
METHODS: This single-center study is a prospective transversal evaluation of pediatric CKD patients of our center, part of the European 4C study. In addition to clinical and biochemical data, vascular and bone evaluation was performed: 24-h blood pressure assessment, carotid intima-media thickness (cIMT), pulse wave velocity (PWV), and high-resolution peripheral quantitative computed tomography (HR-pQCT) at the ultra-distal tibia. Results are presented as median (range).
RESULTS: At a median age of 12.9 years (10.2-17.9), SDS height of - 1.0 (- 3.3-1.2) and estimated glomerular filtration rate (eGFR) of 33 mL/min/1.73m2 (11-72), 32 patients (8 girls) were evaluated. Median calcium, phosphate, parathyroid hormone (PTH), and 25 OHD3 levels were 2.44 mmol/L (2.24-2.78), 1.43 mmol/L (1.0-2.7), 80 pg/mL (9-359), and 70 nmol/L (32-116), respectively. Bivariate Spearman and backward multivariable analyses showed that calcium and bone trabecular thickness (Tb.Th), were positively associated with diastolic and mean arterial blood pressure (both for the 24 h, day and night assessment), whereas PTH and vitamin D did not predict blood pressure.
CONCLUSIONS: We show that the greater the serum levels of calcium, the greater the (diastolic and mean) blood pressure; moreover, the greater the Tb. Th, the greater the (diastolic and mean) blood pressure. The role of calcium supplements to explain such findings in early pediatric CKD can be discussed.

Entities:  

Keywords:  Blood pressure; Bone; Chronic kidney disease–mineral bone disorder (CKD-MBD); HR-pQCT; Vessels

Mesh:

Substances:

Year:  2018        PMID: 29872964     DOI: 10.1007/s00467-018-3978-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  49 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.

Authors:  Stephanie Boutroy; Mary L Bouxsein; Francoise Munoz; Pierre D Delmas
Journal:  J Clin Endocrinol Metab       Date:  2005-09-27       Impact factor: 5.958

3.  Volumetric bone mineral density and bone structure in childhood chronic kidney disease.

Authors:  Rachel J Wetzsteon; Heidi J Kalkwarf; Justine Shults; Babette S Zemel; Bethany J Foster; Lindsay Griffin; C Frederic Strife; Debbie L Foerster; Darlene K Jean-Pierre; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

4.  Ultradian but not circadian blood pressure rhythms correlate with renal dysfunction in children with chronic renal failure.

Authors:  Elke Wühl; Charlotte Hadtstein; Otto Mehls; Franz Schaefer
Journal:  J Am Soc Nephrol       Date:  2005-01-12       Impact factor: 10.121

5.  Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease.

Authors:  Mieczyslaw Litwin; Elke Wühl; Claudia Jourdan; Anna Niemirska; Jens P Schenk; Katarzyna Jobs; Ryszard Grenda; Zbigniew T Wawer; Pawel Rajszys; Otto Mehls; Franz Schaefer
Journal:  Nephrol Dial Transplant       Date:  2008-03-14       Impact factor: 5.992

Review 6.  Cardiovascular risk assessment in children with chronic kidney disease.

Authors:  Rukshana Shroff; Arianna Dégi; Andrea Kerti; Eva Kis; Orsolya Cseprekál; Kálmán Tory; Attila J Szabó; George S Reusz
Journal:  Pediatr Nephrol       Date:  2012-10-16       Impact factor: 3.714

7.  Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.

Authors:  G de Simone; R B Devereux; S R Daniels; M J Koren; R A Meyer; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

8.  Determinants of the intima-media thickness in children and adolescents with chronic kidney disease.

Authors:  Helena Ziolkowska; Michal Brzewski; Maria Roszkowska-Blaim
Journal:  Pediatr Nephrol       Date:  2008-01-29       Impact factor: 3.714

9.  Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients.

Authors:  J Braun; M Oldendorf; W Moshage; R Heidler; E Zeitler; F C Luft
Journal:  Am J Kidney Dis       Date:  1996-03       Impact factor: 8.860

Review 10.  Mechanistic insights into vascular calcification in CKD.

Authors:  Rukshana Shroff; David A Long; Catherine Shanahan
Journal:  J Am Soc Nephrol       Date:  2012-11-08       Impact factor: 10.121

View more
  4 in total

Review 1.  Treatment of hyperphosphatemia: the dangers of high PTH levels.

Authors:  Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2019-11-06       Impact factor: 3.714

Review 2.  Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.

Authors:  Justine Bacchetta; Julie Bernardor; Charlotte Garnier; Corentin Naud; Bruno Ranchin
Journal:  Calcif Tissue Int       Date:  2020-01-29       Impact factor: 4.333

Review 3.  Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?

Authors:  A D Lalayiannis; N J Crabtree; M Fewtrell; L Biassoni; D V Milford; C J Ferro; R Shroff
Journal:  Pediatr Nephrol       Date:  2019-06-25       Impact factor: 3.714

Review 4.  Reducing the burden of cardiovascular disease in children with chronic kidney disease: prevention vs. damage limitation.

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.